One amino acid difference is critical for suppression of the development of experimental autoimmune diabetes (EAD) with intravenous injection of insulinB:9-23 peptide.
Biochem Biophys Res Commun
; 374(3): 581-6, 2008 Sep 26.
Article
en En
| MEDLINE
| ID: mdl-18647597
ABSTRACT
InsulinB9-23 peptide (insB9-23) reactive T cells has been reported as crucial for type 1 diabetes. In this study, experimental autoimmune diabetes (EAD) mice, which subcutaneous immunization of ins1 or 2B9-23 induced autoimmune diabetes in F1(B7.1B6 x BALB/c), was investigated for antigen specific therapy to delete pathogenic T cells. Intravenous injection of ins1 or 2B9-23 significantly delayed the development of diabetes on the corresponding peptide-induced EAD (ins1EAD or ins2EAD) concomitant with reduced insulitis and insulin autoantibodies expression. Population of Foxp3(+) CD4(+) T cell was unchanged whereas the level of anti-insB9-23 specific IgG(2a) but not IgG(1) were specifically decreased, suggesting reduction of pathogenic insB9-23 reactive T cells. Most interestingly, intravenous administration of ins2B9-23, whose amino acid sequence had one amino acid difference at position 9 delayed the development of diabetes in both ins1EAD and ins2EAD whereas ins1B9-23 administration delayed diabetes in the ins1EAD but not ins2EAD, suggesting that one amino acid difference gives critical influence on the effect of intravenous injection of antigenic peptide for type 1 diabetes.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fragmentos de Péptidos
/
Diabetes Mellitus Experimental
/
Diabetes Mellitus Tipo 1
/
Insulina
Límite:
Animals
Idioma:
En
Revista:
Biochem Biophys Res Commun
Año:
2008
Tipo del documento:
Article
País de afiliación:
Japón